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Sustained virological response (SVR) improves survival in post-liver transplant (LT) recurrent hepatitis C. However, the impact of SVR on fibrosis regression is not well defined. In addition, the performance of noninvasive methods to evaluate the presence of fibrosis and portal hypertension (PH) post-SVR has been scarcely evaluated. We aimed to investigate the degree of fibrosis regression (decrease 1 METAVIR stage) after-SVR and its associated factors in recurrent hepatitis C, as well as the diagnostic capacity of noninvasive methods in the assessment of liver fibrosis and PH after viral clearance. We evaluated 112 hepatitis C virus-infected LT recipients who achieved SVR between 2001 and 2015. A liver biopsy was performed before treatment and 12 months post-SVR. Hepatic venous pressure gradient (HVPG), liver stiffness measurement (LSM), and Enhanced Liver Fibrosis (ELF) score were also determined at the same time points. Sixty-seven percent of the cohort presented fibrosis regression: 43% in recipients with cirrhosis and 72%-85% in the remaining stages (P 5 0.002). HVPG, LSM, and ELF significantly decreased post-SVR. Liver function significantly improved, and survival was significantly better in patients achieving fibrosis regression. Baseline HVPG and LSM as well as decompensations before therapy were independent predictors of fibrosis regression. One year post-SVR, LSM had a high diagnostic accuracy to discard the presence of advanced fibrosis (AF) and clinically significant PH (AUROC, 0.902 and 0.888). Conclusion: In conclusion, SVR post-LT induces fibrosis regression in most patients, leading to significant clinical benefits. Pretreatment HVPG and LSM are significant determinants of the likelihood of fibrosis regression. Finally, LSM accurately predicts the presence of AF and PH 1 year after SVR and thus can be used to determine monitoring strategies. (HEPATOLOGY 2018; 67:1683 -1694 ).
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A ntiviral therapy (AVT) against hepatitis C virus (HCV) has dramatically changed in the last few years. The excellent safety profiles and the high efficacy of the interferon (INF)-free directacting antiviral (DAA) regimens markedly increase the possibilities of viral eradication even in patients with severe liver disease or liver transplant (LT) recipients, representing a radical change compared to the treatment possibilities available in the INF era. (1) (2) (3) The impact of viral eradication post-LT has been described in some studies with a limited sample size, revealing a lower probability of decompensation and Abbreviations: AF, advanced fibrosis; AUROC, area under the receiver operator characteristic curve; AVT, antiviral therapy; CSPH, clinically significant portal hypertension; DAA, direct-acting antivirals; DOR, diagnostic odds ratio; ELF, enhanced liver fibrosis; FCH, fibrosing cholestatic hepatitis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HVPG, hepatic venous pressure gradient; INF, interferon; IQR, interquartile range; LSM, liver stiffness measurement; LT, liver transplant; MELD, Model for End-Stage Liver Disease; NPV, negative predictive value; PH, portal hypertension; PPV, positive predictive value; Se, sensitivity; Sp, specificity; SVR, sustained virological response; SVR12, HCV-RNA undetectability 12 weeks after completing therapy.
graft loss as well as the possibility of fibrosis regression in liver recipients who achieve sustained virological response (SVR). (4) (5) (6) (7) (8) However, there are no studies directly aimed at evaluating the probabilities of fibrosis regression, nor the variables that influence such probabilities. In addition, the screening and follow-up of patients after SVR in recurrent hepatitis C has not been defined, because there are scarce data on the performance of noninvasive methods after viral eradication. (9) This is particularly relevant from a clinical point of view, because these methods could impact decision making in a population that, given the efficacy of DAA post-LT, will be increasing in the next years.
In this context, we aimed to describe the degree of fibrosis regression post-SVR and its associated baseline factors in posttransplant hepatitis C, paying particular attention to patients with graft cirrhosis, as well as to evaluate the performance of noninvasive methods to determine the presence of advanced fibrosis (AF) and clinically significant portal hypertension (CSPH) 1 year post-SVR.
Materials and Methods

PATIENTS
We evaluated all HCV-infected LT recipients undergoing AVT between 2001 and June 2015 who achieved viral eradication, defined as HCV-RNA undetectability 12 weeks after completing therapy (SVR12). Patients without fibrosis at pretreatment biopsy as well as those with a biopsy sample size <10 mm and less than six portal tracts either at baseline assessment or at follow-up (nonevaluable biopsies) were excluded from the study. In addition, we excluded patients with fibrosing cholestatic hepatitis (FCH), considering that the METAVIR classification was not designed to describe fibrosis in this particular condition, and thus changes in fibrosis would not be properly evaluated.
BASELINE ASSESSMENTS
Pretreatment assessment included a liver biopsy and, since 2007, a liver stiffness measurement (LSM) with FibroScan (Echosens, Paris, France). In addition, a fasting serum sample was obtained and kept at -808C to calculate the Enhanced Liver Fibrosis (ELF) score (ADVIA Centaur; Siemens Healthcare Diagnostics, Tarrytown, NY) according to the published algorithm. Liver biopsies were obtained either percutaneously or by the transjugular approach, depending on the characteristics and preferences of the patient. In patients undergoing the latter approach, the hepatic venous pressure gradient (HVPG) was also measured. Liver fibrosis was scored according to the METAVIR classification, and the Laennec staging system was also applied in patients with cirrhosis. Liver biopsies were read and staged by two pathologists blinded from treatment status and biopsy timing. HVPG measurements and transient elastography were performed as described previously.
POST-SVR ASSESSMENT
Twelve months after SVR12, the same assessments were repeated. Post-SVR HVPG measurement was only performed in patients with pretreatment portal hypertension (PH; HVPG 6 mm Hg), whereas liver biopsy was only performed if at least portal fibrosis (F 1) was present at pretreatment evaluation.
TREATMENT REGIMENS
The INF-based treatment schedules in our Unit have been described. (4, 14) With regard to the INF-free regimens, we used different regimens according to the drugs approved in Spain, financial disposal, and compassive and expanded-access programs. (15, 16) Treatment duration and ribavirin use was at physician discretion according to the European Association for the Study of the Liver guidelines. (15) EVALUATION OF OUTCOMES 1. Changes in fibrosis: the main outcome was the evaluation of fibrosis regression, according to changes in histology (METAVIR score) as follows:
-Fibrosis regression: decrease of 1 stage in the METAVIR score at follow-up biopsy. (17, 18) -Fibrosis stabilization: same METAVIR score in the post-SVR biopsy with respect to pretreatment biopsy.
-Fibrosis worsening: increase of 1 stage in the METAVIR score at follow-up.
Changes in elastography:
Changes in liver stiffness were evaluated as the percentage of change in posttreatment assessment with respect to pretreatment evaluation. A reduction in liver stiffness of at least 30% compared to pretreatment evaluation was considered clinically significant. (19, 20) 3. Changes in HVPG were evaluated as follows:
-HVPG response: reduction of the basal value 20% in the follow-up evaluation. 
ETHICAL CONSIDERATIONS
The study was performed in accord with the Declaration of Helsinki and the E6 Good Clinical Practice Standards ICH. All personal data were codified in accord with the Organic Law 15/1999 of 13 December on the Protection of Personal Data in Spain. All the study data were treated anonymously with restricted access by only authorized personnel for the purposes of the study. All patients were properly informed about the study and provided written consent for inclusion. The study was approved by the Clinical Research Ethical Committee of the Hospital Clinic of Barcelona (Barcelona, Spain).
STATISTICAL ANALYSIS
Median and interquartile range (IQR) were used to describe quantitative variables, and number of cases and percentages were used for qualitative variables. The differences between the qualitative variables were compared using the chi 2 -test or Fisher's exact test or McNemar's test when indicated. The qualitative variables were analyzed by means of a nonparametric test (Mann-Whitney or Kruskall-Wallis for unpaired samples, and Wilcoxon for paired samples). Multivariate analysis was performed to evaluate variables associated with fibrosis regression, including variables with a P value 0.1 at univariate analysis as well as those considered clinically significant. The Kaplan-Meier estimator of the distribution of survival time was used to calculate patient survival over time. The log-rank test was used to compare survival distributions. The diagnostic accuracy of ELF and elastography to diagnose the presence of AF (F3/F4) and CSPH was assessed by calculating the areas under the receiver operator characteristic curve (AUROC). The best cut-off values of ELF were determined by optimization of the Youden index, and sensitivity (Se), specificity (Sp), and positive and negative predictive values (PPV, NPV) were calculated from these same data. With regard to LSM, the best cutoffs to rule out and rule in AF and CSPH were selected according to the sensitivity and specificity values, respectively. In addition, previously described cutoffs for CSPH and AF (compensated advanced liver disease) were also evaluated. (21) (22) (23) Positive and negative likelihood ratios (LR 1 , Se/(100-Sp); LR -, (100-Se)/Sp) were calculated based on the respective sensitivity and specificity values. The diagnostic odds ratio (DOR) was calculated by dividing the LR 1 by the LR -. Comparisons of AUROCs were performed according to the DeLong method. (24) All tests were two-tailed, and a P value below 0.05 was considered statistically significant. SPSS version 20 (IBM Statistics, Armonk, NY, USA) was used to perform the statistical analysis, except for AUROC comparisons, which were performed with VassarStats(Vassar College, Poughkeepsie, NY, USA). (25) 
Results
PATIENTS
A flow chart of the study is shown in Fig. 1 . One hundred twelve patients who achieved SVR during the study period and who had pretreatment and 12-month posttreatment liver biopsies were included in the study. Among these patients, 52 achieved SVR12 under INFbased therapies and 60 with INF-free regimens ( Table  1) . As expected, given the indications and contraindications of the different schemes and their different efficacy, patients who achieved SVR after treatment with INF were less frequently patients with cirrhosis and had a significantly lower HVPG and LSM as well as a lower Child-Pugh score and lower Laennec stage than those treated with INF-free regimens (data not shown). There were no statistically significant differences between patients included in the study and those not included because of the absence of follow-up biopsy.
FIBROSIS REGRESSION
Before AVT, F1, F2, F3, and F4 were present in 16%, 28%, 23%, and 33% of the cohort, respectively, whereas the prevalence of the same stages in the follow-up assessment was 18%, 21%, 15%, and 20%, respectively, with 26% of patients presenting F0 at follow-up ( Fig. 2A ; P < 0.001). Table 2 shows the changes in fibrosis according to baseline stage. Sixtyseven percent of the cohort presented fibrosis regression, 31% stabilization, and only 2% presented worsening. The probability of fibrosis regression was significantly lower in those with baseline graft cirrhosis: 43% of patients with graft cirrhosis presented fibrosis regression, whereas the probability of fibrosis regression in the remaining stages ranged from 72% to 85% (P 5 0.002; Fig. 2B ).
CHANGES IN HVPG
Fifty-one patients had paired HVPG measurements before and after SVR. Baseline fibrosis staging in these patients was: F4 (n 5 25), F3 (n 5 11), F2 (n 5 10), and F1 (n 5 5). The median HVPG significantly decreased from 8.5 (6.5-12.5) to 6.0 (4.0-10.5) mm Hg (P < 0.001) after SVR, and 66% of patients presented HVPG response. The baseline HVPG was significantly lower in patients with fibrosis regression (n 5 28) than in those without (n 5 23): 7.3 (6-10) versus 11.5 (8.0-15.5) mm Hg (P < 0.001). Similar to 
Abbreviations: PT, prothrombin time; Tac, tacrolimus; CyA, cyclosporine; PegINF, pegylated interferon; RBV, ribavirin; BOC, boceprevir; TLV, telaprevir; SOF, sofosbuvir; DCV, daclatasvir; SMV, simeprevir; LDV, ledipasvir; 3D, ombitasvir, paritaprevir, ritonavir, and dasabuvir; NA, not applicable.
the results reported by Mandorfer et al. in immunocompetent patients, median decrease in HVPG was 31% (range, 17-51). (26) The highest decrease was observed in patients with mild PH at baseline (6.0-9.9 mm Hg): 42% (range, 20-58). However, even in patients with severe PH (HVPG 16 mm Hg), the decrease in HVPG was significant: 26% (range, 2-37), although it must be stressed that only 6 patients had a baseline HVPG 16 mm Hg.
In the subgroup of patients with F4 and paired HVPG (n 5 25), the HVPG decreased from 12 (7.5-16.0) to 8.5 (6-11) mm Hg (P < 0.001), and HVPG response was present in 64%. Baseline HVPG was significantly lower in patients with cirrhosis regression (n 5 9; 7.5 [6.25-13 .00] mm Hg) than in those who did not achieve cirrhosis regression (n 5 16; 14 [11.5-16-7] mm Hg; P 5 0.004).
CHANGES IN LIVER STIFFNESS
Eighty-four patients had paired LSM before and after SVR. Median stiffness decreased from 15.7 (10.1-26.0) to 8.2 (6.2-14.5) kPa (P < 0.001) after SVR, and 67% of the cohort presented elastographic response. Baseline liver stiffness was significantly lower in patients with fibrosis regression (n 5 53; 12.6 [9.1-20.7] kPa) than in those who did not achieve fibrosis regression (n 5 31; 26 [13.0-32.5] kPa; P < 0.001).
We also evaluated the dynamic changes in LSM and their association with fibrosis regression. Median LSM decrease in patients with fibrosis regression was 47% (range, 30-61), being 30% (range, 18-47) in patients without regression (P 5 0.02). The AUROC of the % decrease in LSM to predict fibrosis regression was 0.653 (0.545-0.772). A decrease of 50% in baseline LSM obtained a PPV of 78% to predict fibrosis regression, with an NPV of 44%, and could correctly classify 55% of patients.
In patients with cirrhosis (n 5 34), LSM decreased from 25.3 (16.5-32.8) to 14.5 (9.9-22.1) kPa (P < 0.001), with 62% of patients with cirrhosis presenting elastographic response. The baseline differences in LSM between patients with cirrhosis with (n 5 14) and without fibrosis regression (n 5 20) were also statistically significant: 17.1 (13.0-21.6) versus 26.6 kPa (25.3-35.6; P 5 0.003), respectively.
CHANGES IN ELF SCORE
Ninety-six patients had paired ELF measurements before and after SVR. Median ELF score significantly decreased from 11.5 (10.6-12.8) to 10.2 (9.5-11.2; P < 0.001) after SVR, and the median percentage of decline was 10.8% (4.5-16.2). We did not find a significant association between the baseline ELF score and fibrosis regression.
In the subgroup of patients with graft cirrhosis and paired ELF (n 5 34), the ELF score decreased from 12.3 (11.2-13.2) to 11.1 (10.4-12.2; P < 0.001), and the median percentage of decline was 7.8% (3.1-13.2). Baseline ELF was not associated with cirrhosis regression.
CLINICAL OUTCOMES
Fifty-one percent of patients with cirrhosis underwent treatment after clinical decompensation, whereas the proportion of baseline patients with cirrhosis presenting decompensation at follow-up was 5% (P < 0.001). Similarly, Child-Pugh score decreased from 6 (5-7) to 5 (5-7; P 5 0.015) points, and Model for End-Stage Liver Disease (MELD) score fell from 10 (9-13) to 9 (8-11; P 5 0.035). A trend toward a better survival was observed in patients with cirrhosis with regression of fibrosis compared with patients with cirrhosis who remained with cirrhosis after SVR (Supporting Fig. S1A ), probably attributed to the short follow-up (most patients with cirrhosis achieved SVR when treated in the DAA era) and the low number of events (P 5 0.19). Indeed, on evaluating survival in the whole cohort, patients with fibrosis regression had a significantly better survival than those in whom fibrosis did not regress despite SVR (Supporting Fig. S1B) . Four of the 75 (5%) patients with fibrosis regression died during follow-up: 2 because of cardiovascular disease, one in the setting of chronic rejection and another in the setting of idiopathic PH. In contrast, 5 of 37 (13%) patients without regression died: 1 because of hepatocellular carcinoma (HCC) recurrence and 4 because of complications of cirrhosis. Two patients were considered for liver retransplantation, but because of clinical improvement neither was finally included on the waiting list.
VARIABLES ASSOCIATED WITH FIBROSIS REGRESSION
The baseline variables inversely associated with fibrosis regression in the whole population at univariate analysis were the presence of cirrhosis, the HVPG, liver stiffness, hepatic decompensations, and the time between transplant and effective AVT (Table 3 ). In addition, the type of treatment was also associated with fibrosis regression. However, on multivariate analysis, the only independent variable associated with fibrosis regression was the baseline HVPG, either as a continuous variable or categorized as the presence or absence of CSPH. Taking into account that the HVPG was not determined in a proportion of patients and also that measurement of the HVPG is an invasive procedure not available in all centers, we performed the multivariate analysis excluding this variable. In this case, a LSM <21 kPa (the cutoff commonly accepted to predict CSPH) (27) and the absence of decompensations before therapy were identified as independent predictors of fibrosis regression. In the subpopulation of patients with cirrhosis, the baseline variables inversely associated with fibrosis regression at univariate analysis were the Child-Pugh score, Laennec classification, the HVPG, liver stiffness, and the presence of hepatic decompensations before AVT. Considering the low number of events (16 patients with cirrhosis with regression), a multivariate analysis was not performed in this subpopulation. Nevertheless, Laennec stage, an HVPG <10 mm Hg, and an LSM cutoff of 21 kPa accurately predicted the possibility of regression of cirrhosis (Fig. 3) .
ACCURACY OF NONINVASIVE METHODS AFTER SVR
The characteristics of the cohort 12 months after SVR are shown in Table 1 . The distribution of LSM and ELF values according to each METAVIR stage is shown in Supporting Fig. S2 , whereas the correlation between HVPG and either LSM or ELF is shown in Supporting Fig. S3 . LSM was highly accurate to diagnose and discard the presence of AF 1 year after SVR, with an AUROC of 0.902 that was significantly higher than that of ELF (Fig. 4) . The best LSM cutoffs to rule out and rule in AF were, respectively, 10.6 and 14 kPa. The performance of these cutoffs was similar to the thresholds recommended by Baveno statements (10 and 15 kPa; Table 4 ). In the diagnosis of CSPH, both noninvasive methods were highly accurate: The AUROC of LSM and ELF were 0.888 and 0.884 (P 5 0.959), respectively. For LSM, a cutoff of 11.3 kPa was highly accurate to rule out the presence of CSPH, whereas a cutoff of 23 kPa could confidently rule in the presence of CSPH. Again, the performance of these thresholds was similar to that of the cutoffs commonly used in clinical practice (13.6 and 21 kPa).
Discussion
We evaluated the impact of viral eradication on fibrosis regression 12 months after SVR in a large, single-center cohort of LT recipients with recurrent hepatitis C, and found that fibrosis regression takes place in the majority of patients. Importantly, fibrosis regression was also observed in patients with cirrhosis 
FIG. 4. AUROCs of LSM and ELF in the diagnosis of AF (A) and CSPH (B).
after SVR, although with a lower frequency when compared with recipients without cirrhosis. Fibrosis regression is further accompanied by a decrease in portal pressure, liver stiffness, and the ELF score as a biomarker of fibrogenesis. In addition, our results show that pretreatment variables, particularly an HVPG 10 mm Hg and LSM 21 kPa as well as liver decompensations before treatment, can identify patients with a lower likelihood of fibrosis regression. Finally, we show that 1 year after SVR, LSM is particularly useful to assess advanced graft disease, because it can confidently discard and diagnose the presence of AF and CSPH. This latter finding is particularly important from a clinical point of view, given that it can have a potential impact in the follow-up strategies after SVR.
In the setting of recurrent hepatitis C, the evidence of the histological and hemodynamic impact of SVR is limited and comes from small studies in the INF era. (4, 14, 28) Very recently, a study with noninvasive methods in a population of 126 HCV-infected recipients treated with sofosbuvir-based therapies reported an improvement in the estimation of fibrosis with FibroScan, Fibrosis-4, and aspartate aminotransferaseto-platelet ratio index in approximately half of the patients with baseline AF; however, paired biopsies were not performed in this study. (29) Our results show that LT recipients with cirrhosis, half of whom were decompensated, still have a 40% probability of histologically defined fibrosis regression 1 year after SVR. However, the more advanced the disease, the lower the possibility of fibrosis regression, and this was demonstrated in several ways: Previous decompensations, baseline HVPG, and baseline LSM were inversely associated with fibrosis regression. In addition, the Child-Pugh classification and the Laennec stage were also inversely associated with fibrosis regression on univariate analysis in the subpopulation of patients with cirrhosis. Indeed, the presence of thick fibrous septa in patients with cirrhosis may be indicative of a point of no return, where even in the absence of a trigger (HCV), collagen resorption is slower or even absent. When all the variables were introduced in a multivariate model, the baseline HVPG was the only independent predictor of absence of fibrosis regression in the whole population, whereas LSM and decompensations were independent inverse predictors of regression if HVPG was excluded from the model. Although the type of treatment (INF vs. INF-free) was associated with fibrosis regression at univariate analysis, this association was no longer significant in the multivariate analysis, because the baseline indicators of advanced disease were different in the two populations.
As an invasive estimate of portal pressure, the HVPG is the most accurate determinant of prognosis in chronic liver disease, (30) and, according to our results, it is also the most powerful predictor of fibrosis regression. Indeed, recipients with cirrhosis and CSPH only had an 18% probability of cirrhosis regression as compared with the remaining population of patients with cirrhosis, whose possibilities of cirrhosis regression were as high as 70%, similar to the population of patients without cirrhosis. This paralleled the probabilities of cirrhosis regression according to Laennec staging, ranging from 0% in Laennec C to 78% in Laennec A. Not less importantly, and considering that HVPG measurement is an invasive procedure not available in all centers, we found that easy, noninvasive methods such as LSM are also useful to estimate the probability of cirrhosis regression in the LT setting. Thus, pretreatment evaluation with LSM seems to be useful not only to accurately diagnose the presence of PH or the fibrosis stage, but also to predict the possibilities of histological improvement posttherapy.
In contrast with the setting of active hepatitis C either in immunocompetent patients or transplant recipients, in whom the accuracy of LSM has been widely validated, (31, 32) the use of noninvasive methods to screen the presence of cirrhosis, PH, or AF after SVR is currently not recommended because the data available to date are scarce. (20, 33) Considering this, we evaluated the performance of LSM and ELF after SVR, and showed that LSM is able to accurately discard and diagnose the presence of advanced graft fibrosis and CSPH, whereas ELF also proved useful to rule out the presence of CSPH. In this regard, the best cutoff values of LSM to rule in or rule out the presence of CSPH or AF after SVR need to be further evaluated. However, the diagnostic performance of the best cutoffs derived in our population seemed to be equivalent to that of the commonly used cutoffs in HCV patients. Indeed, these thresholds were also very similar to the values reported in the only study to date that has proposed cut-off values of LSM for CSPH after SVR, although that study included immunocompetent patients with cirrhosis evaluated at different time points after SVR. (26) In fact, although the study by Mandorfer et al. also suggested a role of LSM to evaluate the presence of PH after SVR in immunocompetent patients, our results are in contrast with recent data that showed that LSM after viral eradication was not as accurate to exclude CSPH. (34) This may reflect the differences in liver fibrogenic responses between the two populations: the speed of fibrosis deposition and probably regression are faster in liver transplant recipients, and the presence of sinusoidal fibrosis, that is much more common in LT recipients. Indeed, LSM may better mirror fibrosis regression in the latter population. Our results may have a clear clinical implication given that they may help to define the prognosis of patients, including the determination of those patients who should be monitored for complications of PH. (9) Although the clinical impact of our results will be driven by demonstrating, in longer follow-up studies, that the use of noninvasive methods after SVR contributes to confidently exclude future variceal bleeding, clinical decompensation, or development of HCC, our results support the use of noninvasive methods 12 months after SVR in recurrent hepatitis C to confidently assess the graft condition, attending the significant association between such methods and the histological and hemodynamic evaluation of the graft. Nevertheless, it is clear that studies with larger sample sizes and longer follow-up are necessary to establish the role of noninvasive methods in the follow-up of LT recipients after viral clerarance. In addition, the possibility of further improvements in fibrosis and portal pressure in the long term after SVR and their potential implications in the accuracy of noninvasive methods should also be investigated.
Interestingly, although necroinflammatory stage improved in 63% of patients, a significant proportion of patients remained with persistent necroinflammation in the follow-up biopsy despite SVR (Table 1) , not being associated with fibrosis regression or persistence of PH. This fact has already been reported in this and other settings and is difficult to explain. (35) (36) (37) In addition, the consequences of persistent necroinflammation are unknown. In the context of recurrent hepatitis C, occult hepatitis C infection despite SVR has been linked to increases in transaminases and features of chronic hepatitis in liver histology, (38) and the persistent necroinflammation in HCV-negative LT recipients may also be associated with immunological phenomena, mainly described in the INF era. (39) The investigation of the pathogenesis and clinical consequences of persistent necroinflammation despite SVR in recurrent hepatitis C could be the focus of further, directly aimed studies.
Recent international guidelines recommend investigating the impact of viral eradication with DAA on clinical outcomes, particularly in patients with decompensated disease. (40) (41) (42) In this regard, our results confirm the improvements in clinical status and liver function parameters accompanying viral eradication post-LT described in other studies. (6) (7) (8) 43) Although these improvements are mild in terms of prognostic scores, they result in a clear benefit in terms of clinical decompensations, and indeed no patient in this cohort required retransplantation. Furthermore, we showed that fibrosis regression is responsible for a significant survival benefit attributed to a decrease in liver-related deaths. These results are in line with those reported by Dhanasekaran et al., who, in a cohort of LT recipients treated in the INF era, showed that progression of fibrosis is associated with a worse survival, independently of the achievement of SVR. (44) Nevertheless, considering that half of the cohort achieved SVR with the new DAAs and thus the follow-up was relatively short, a longer follow-up of these patients is still mandatory to confirm the benefit in survival obtained by patients achieving fibrosis regression.
The main limitation of our study is the use of liver biopsies and semiquantitative methods to define fibrosis regression, which do not allow the exclusion of sampling bias and intra-and interobserver discordances. Furthermore, the exclusion of patients without fibrosis or PH at baseline does not exclude the possibility of disease progression and thus does not permit us to provide the complete picture, although it must be stressed that fibrosis worsening only took place in 2% of our patients. In contrast, we characterized fibrosis regression in several different ways, allowing not only to show a clear correlation between the different methods, but also to comprehensively describe the process of changes in portal pressure, liver stiffness, and biomarkers of fibrogenesis in this setting. In addition, the currently accepted gold standard for evaluating regression is still the decrease of at least one stage of fibrosis in semiquantitative scores. (17) Another limitation of the study is that we performed the assessment of regression and the accuracy of noninvasive methods at a single time point. (45) Further longitudinal studies should be performed, given that fibrosis regression may continue over time, as shown in chronic hepatitis B. (46) On the other hand, the fact that we evaluated a large cohort of recipients, at the same time point and using several methods, clearly strengthens our results. Finally, the large time period of inclusion and the use of different antiviral regimens, including INF-based and some DAA combinations that are no longer used presently, may also limit our results. However, it should be stressed that the evaluation of fibrosis regression was uniform in the cohort and particularly that, although on univariate analysis the type of treatment (INF vs. DAAs) was associated with fibrosis regression, multivariate analysis demonstrated that the type of treatment was a confounder attributed to the different characteristics in terms of disease severity.
In conclusion, we have shown that fibrosis regression is frequent in recurrent hepatitis C 1 year after achieving viral eradication, even in patients with decompensated disease, results in significant clinical benefits, and can be anticipated using the HVPG or LSM. In addition, our results suggest that post-SVR LSM may play a significant role in the monitoring and follow-up of LT recipients.
